ROCKVILLE, Md. -- InforMedix Holdings, Inc. (OTCBB: IFMX) announced today that it will co-brand its Med-eMonitor(TM) patient diary and medication dispensing device with McKesson BioServices, a division of McKesson. McKesson BioServices, with its expertise in specialty clinical trial material packaging and medication distribution systems, will market, sell and distribute the co-branded device to facilitate clinical trials.
The "McKesson Med-eMonitor" is the first device that integrates medication packaging, medication compliance, and an electronic patient diary, resulting in improved medication compliance and capture of patient dose-response data. Improved medication compliance reduces the variability of the data, which, in turn, reduces the number of patients needed to demonstrate statistical significance. The end result is faster, less expensive clinical trials.
"We are excited about working more closely with InforMedix," said Pat Hindes, marketing manager for McKesson BioServices. "The co-branding of the Med-eMonitor device reinforces our dedication to patient safety and strengthens our presence in the clinical trial market."
Additional features of the device include the ability to record the exact time of dosing and deliver a therapy which uses more than one drug; rapid and accurate reporting of adverse experiences; the potential to detect medication compliance problems and to quickly develop protocol changes. Med-eMonitor is also ideal for disease management programs because it can identify medication compliance issues and prompt interventions before poor compliance leads to further health problems.
"We are extremely pleased that McKesson is lending its reputation and expertise to assist InforMedix in providing the McKesson Med-eMonitor device for use in clinical trial patient monitoring and data capture," said Dr. Bruce Kehr, CEO of InforMedix.
About InforMedix
InforMedix has developed the Med-eMonitor System to provide real-time medical management and patient communications for clinical drug trials. InforMedix has integrated a portable patient-interactive monitoring device, hardware, software and networked communications system to enable pharmaceutical and biotechnology companies, medical researchers, and disease management programs to efficiently monitor and manage patients' medication compliance, protocol adherence, clinical response, and safety. Med-eMonitor is specifically designed to improve patient medication compliance and protocol adherence in clinical drug trials and disease management programs. The Med-eMonitor System leverages InforMedix's strong intellectual property consisting of 15 issued patents and 14 patents pending. InforMedix's patents have been cited as prior art by patent examiners in over 150 other issued patents. To find out more about InforMedix, Inc. (OTCBB: IFMX), visit our website at www.informedix.com.
About McKesson BioServices
Understanding the critical drug development process, McKesson BioServices experienced staff has extensive domestic and worldwide shipping expertise working closely with clients to support any clinical trial and address special needs involved in handling clinical trial material. McKesson BioServices is a leader in the management, packaging and labeling, analytical testing, validation testing, storage and distribution of clinical trial materials and biological specimens covering preclinical through Phase IV studies. BioServices also provides patient-specific pharmacy services nationwide to support patient assistance programs for commercial pharmaceutical products. For information about McKesson BioServices' wide array of services, visit www.mckessonbio.com.
InforMedix Safe Harbor Provisions
This report contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. These statements include the McKesson Med-eMonitor resulting in improved patient medication compliance and capture of patient dose-response data; the end result is faster, less expensive clinical trials; and the potential to detect medication compliance problems and to quickly develop protocol changes. References made to the discussion of the risk factors are detailed in the Company's filings with the Securities and Exchange Commission, including the report on Form 10-QSB for the quarter ended September 30, 2004, our Annual Report on Form 10-KSB for the year ended December 31, 2003, our prospectus dated May 28, 2004 and our other filings with the U.S. Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.
|